In a move that highlights the sturdiness of public-private teamwork


web office collaborationmanage projects in tackling international health challenges, the Maryland-based company Sanaria Inc., with support from the PATH Malaria Vaccine Initiative (MVI), has initiated a Phase 1 clinical trial - the first tests in adult volunteers - of its unique malaria vaccine candidate. Unlike other malaria vaccine candidates, Sanaria's nearness deploys a weakened form of the whole malaria parasite harvested from irradiated mosquitoes instead of small portions of the parasite.

More: - The rest...